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Abstract
Background: The measurement of C-reactive protein 
(CRP) concentrations has been of interest as a classical 
marker of acute phase response; in addition, it has been 
of particular interest in cardiovascular risk stratifica-
tion where high-sensitive measurements are necessary. 
Since CRP is able to bind phospholipids (mainly phos-
phocholine) in the presence of calcium ions, we explored 
the possibilities of developing a high-sensitive afford-
able nephelometric CRP assay based on diluted soy oil 
emulsions.
Methods: Serum (or heparinized plasma) was mixed with 
Intralipid 20% in Tris-calcium buffer (pH 7.5). After 12 min 
of incubation at 37°C, the CRP-phospholipid complexes 
were measured by nephelometry (840 nm) using a BN II 
nephelometer (Siemens). Results (n = 97) were compared 
with those obtained using a typical immunoturbidimetric 
method (Roche).
Results: Imprecision of the functional nephelometric 
assay was evaluated using three human serum pools. 
Within-run coefficients of variation (CVs) for level 1, 
2 and 3 were 6.1%, 4.7% and 4.5%, respectively, and 
between-run CVs were 17.6%, 18.8% and 11.3%, respec-
tively. Good agreement was obtained between the func-
tional nephelometric and the immunoturbidimetric 
CRP assay in a concentration range from 0.1 mg/L to 50 
mg/L (r = 0.884). A logit-log calibration curve was made 
between 0.056 mg/L and 1.785 mg/L. The limit of detec-
tion was 0.5 mg/L.
Conclusions: The functional nephelometric CRP assay 
allowed high-sensitive CRP determinations in serum 
and plasma. Since the assay is species independent, the 
described functional CRP assay could be used for veteri-
nary purposes as well.
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Introduction
C-reactive protein (CRP), the classical marker of acute 
phase response in humans and most animals, is an indi-
cator of a variety of pathologic processes including infec-
tions, tissue damage, and chronic inflammatory diseases 
[1]. Serum CRP concentrations may rise within 24–48  h 
after the acute event and may increase up to a 1000-fold. 
When released in the circulation it is equally distributed 
in the vascular compartment without substantial tissue 
sequestration at sites of inflammation [2]. In addition, 
since the clearance of CRP is monoexponential and inde-
pendent of the serum concentration or pathophysiologi-
cal circumstances, measurement of CRP is a good marker 
of disease activity and it may contribute to the diagnosis 
and management of infectious diseases and other inflam-
matory conditions [2–4].
During the past decade, CRP experienced a revival 
in attention due to its possible role in the inflammatory 
pathogenesis of cardiovascular diseases [2, 5–7]. The CRP 
concentration is supposed to reflect the grade of vulner-
ability and instability of the atherosclerotic plaques, 
leading to rupture, thrombosis and thus, to occlusive 
arterial disease. Since atherosclerosis remains the major 
cause of death in developed countries and despite the 
successful fight against lipid associated risk factors, the 
role of inflammation in atherosclerosis has become more 
evident. High-sensitivity CRP is regarded as an excellent 
parameter to predict the grade of inflammation in relation 
to atherosclerosis and patients with intermediate risk of 
coronary heart disease. Multiple prospective studies in 
initially healthy subjects (excluding active inflammatory 
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conditions) have shown an association between con-
centrations of CRP within the reference range ( < 5 mg/L) 
and future major cardiovascular events. This has led the 
Center for Disease Control and Prevention and the Ameri-
can Heart Association to publish a statement for health 
professionals addressing recommendations for the use of 
CRP measured by high-sensitive assays (hsCRP) in cardio-
vascular risk prediction, particularly among patients at 
intermediate risk of coronary heart disease [5, 8, 9].
Currently, most clinical laboratories predominantly 
rely on automated immunonephelometric and immuno-
turbidimetric assays to quantify CRP concentrations with 
detection limits of 0.3–5 mg/L, depending on the purpose 
of the CRP measurement, e.g., in acute inflammatory 
processes or for cardiovascular risk stratification [9, 10]. 
Several other techniques have been studied, using a wide 
variety of nanoparticles with different detection systems, 
e.g., selective ligands such as phosphocholine or o-phos-
phorylethanolamine and emerging techniques based 
on surface plasmon resonance and molecular imprinted 
polymers; these seemed quite promising due to their short 
reaction time and high sensitivity [10]. In addition, non-
immunological methods are preferable in veterinary med-
icine, since immunoassays are not able to detect CRP from 
unrelated animal species due to the absence of common 
antigenic sites.
Calcium-mediated CRP binding to phosphocholine 
has been the subject of several studies, using different 
reagents such as synthetic globular polymers as scaffolds 
for the phosphocholine molecules, or soy oil emulsions 
[11–13]. Both in vitro and in vivo, CRP has been reported 
to produce agglutination (‘creaming’) of the intravenously 
administered lipid suspension Intralipid [14, 15]. Similarly, 
CRP also produced agglutination of isolated normal very 
low-density lipoproteins (VLDL) [16, 17]. Tugirimana et al. 
developed a manual turbidimetric CRP assay based on 
this agglutination with phosphocholine using Intralipid 
20%, intended for use in Third World district hospitals 
[18]. However, this method had an analytical sensitivity of 
only  ± 7 mg/L, which is slightly above the reference range 
(5 mg/L).
In view of the clinical importance of hsCRP and the 
relatively high above described limit of detection (LOD), 
special attention was paid to develop a method with a 
good analytical sensitivity. Since particle-enhanced neph-
elometry has enabled measuring CRP concentrations as 
low as 10−9 mol/L [19], we explored the possibilities of 
developing an affordable functional method for assaying 
CRP in serum or plasma using soy oil emulsions contain-
ing phosphocholine (Intralipid 20%) as a natural and 
cheap nephelometric reagent.
Materials and methods
Study population
Ninety-seven randomly selected serum samples with varying CRP 
concentrations (mean = 52.0 mg/L, range = 0.7–171.6 mg/L) were 
obtained from the routine laboratory. Venous blood was collected, 
allowed to clot and centrifuged at 2000 g for 20 min. Subsequently, 
the samples were stored at 4°C for up to 1 week prior to testing.
Immunoturbidimetric assay
The latex particle enhanced immunoturbidimetric assay for CRP, 
regarded as a standard technique, was carried out using CRPL3 
reagent (Roche, Mannheim, Germany), with a Cobas 8000 analyzer 
(Roche). The assay has been standardized using a commercial stand-
ard traceable to CRM 470 [20–22] (Roche).
Functional nephelometric CRP assay
Intralipid 20% (Fresenius Kabi, Uppsala, Sweden) is a fat emulsion 
for intravenous infusion containing, per liter, 200  mL of soybean 
oil, 12 mL of egg phospholipids, and 22 mL of glycerin, with the bal-
ance made up by water. Intralipid 20% is stable for at least 6 weeks 
at 37°C. Hydroxymethyl aminomethane (Tris) and calcium chloride 
were purchased from Sigma-Aldrich, sodium chloride was purchased 
from Merck (Darmstadt, Germany).
The functional nephelometric CRP assay was carried out using 
Intralipid 20% and Tris-calcium chloride buffer [Tris (hydroxy-
methyl aminomethane) 0.1 mol/L; calcium chloride 0.1 mol/L; pH 
was adjusted to 7.5 using hydrochloric acid 1 mol/L], on a BNII neph-
elometer (Siemens, Marburg, Germany) using a two-step protocol. 
Intralipid 20% was manually prediluted (1:700) with Tris-calcium 
chloride buffer.
During the first step, 30 µL of serum was mixed with 30 µL of 
0.9% NaCl and 175 µL of Tris-calcium chloride buffer; followed by 
the addition of 50 µL of 0.9% NaCl and 50 µL of prediluted Intralipid 
20% in a second step. The commonly used commercial diluent solu-
tions containing phosphate-buffered saline should not be used for 
the functional CRP assay since they cause, in combination with the 
Tris-calcium chloride buffer, a calcium phosphate precipitate in the 
cuvette, which results in an interference. All serum samples were 
automatically prediluted (1:100) with 0.9% NaCl. CRP concentrations 
were measured nephelometrically after 12 min incubation, based on 
the absolute increase of the nephelometric signal over 12 min. A more 
detailed description of the applied instrument settings can be found 
in Table 1. The functional assay was calibrated using a commercial 
primary standard traceable to CRM 470 (Roche).
Affinity chromatography
In order to obtain CRP-depleted serum, affinity chromatography of 
pooled serum with a low CRP concentration ( < 0.6 mg/L) was carried 
out against phosphocholine containing gel (Thermo Fisher Scien-
tific, Rockford, USA) [23]. A 5-mL column was prepared by packing 
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the phosphocholine containing gel into a disposable column. The 
column was equilibrated by applying two column volumes of bind-
ing buffer (0.1 M Tris buffer, 0.1–0.2 M NaCl, 1–2 mM CaCl2; pH 8). Sub-
sequently, the pooled serum was added to the column, incubated for 
1 h at room temperature and the CRP-depleted serum was collected 
for further research. The column was washed with five column vol-
umes of binding buffer and the bound protein (purified CRP) was 
eluted by substituting EDTA for the Ca2+ in the buffer (elution buffer: 
0.1 M Tris buffer, 0.1–0.2 M NaCl, 2 mM EDTA; pH 8). In addition, the 
CRP concentration of the supposed CRP-depleted serum was subse-
quently measured using the immunoturbidimetric assay on a Cobas 
8000 analyzer and was not detected (0.0 mg/L, LOQ 0.6 mg/L).
Performance characteristics
The limit of blank (LOB) was calculated as the mean value +3 stand-
ard deviation (SD) for a blank sample (CRP-depleted serum). The 
lower LOD and the limit of quantification (LOQ) were calculated 
as the mean value +3SD and as the mean value +6 SD for a sam-
ple with a very low CRP concentration, respectively [24]. Linearity 
was evaluated in the concentration range between 1 and 300 mg/L 
[21]. Within-run (n = 10) and between-run (n = 8) imprecision were 
assessed using human serum pools with CRP concentrations rang-
ing from 2.5 mg/L to 65.8 mg/L. Within-run analysis was performed 
in 1 run in one day and between-run on 4 consecutive days with two 
analyses each day.
Specificity
The purified CRP protein (obtained by affinity chromatography) was 
used to assess the specificity of the assay. In order to investigate the 
possible effects of confounding factors, serum calcium, cholesterol, 
Table 1 Instrument settings for the functional nephelometric CRP 
assay (BNII).
Parameter   Setting
Two-step protocol:  
 Step 1:  
  – 0.9% NaCl   30 µL
  – Tris-calcium chloride buffer   175 µL
  – Sample (serum/plasma)   30 µL
  – Mixing time   default (0.0 s)
 Step 2:  
  – 0.9% NaCl   50 µL
  – Prediluted Intralipid® 20%   50 µL
  – Mixing time   Default (0.6 s)
Intralipid® 20% predilution   1/700 using Tris-calcium 
chloride buffer
Calibration  
 – Start dilution   1/20 using 0.9% NaCl
 – Dilution points   6
 – Concentration range   0.056–1.785 mg/L
Start sample dilution   1/100 using 0.9% NaCl
Reaction time   12 min
Reaction temperature   37°C
high-density lipoprotein (HDL)-cholesterol, triglycerides, phospho-
lipids, and total and direct bilirubin were measured in parallel using 
standard methods. Triglyceride, cholesterol, HDL-cholesterol, total 
and direct bilirubin, and serum calcium concentrations were meas-
ured for all serum samples using a Cobas 8000 analyzer (Roche).
Method comparison
Comparison was carried out between the immunoturbidimetric assay 
(CRPL3, Cobas 8000) and the functional nephelometric CRP assay 
(n = 97) during 3 consecutive days.
Statistics
Data were analyzed using MedCalc® (MedCalc Software, Mariakerke, 
Belgium). Agreement between the functional nephelometric assay 
and the immunoturbidimetric assay was evaluated using Passing-
Bablok regression analysis. Multiple regression analysis was used to 
investigate potential confounding factors; results with a p < 0.05 were 
considered significant.
Results
Performance characteristics
A six-point calibration curve of the nephelometric 
signal (bits, measurement of the scattered light inten-
sity in a fixed angle of 13–24°) and CRP concentra-
tion was constructed (Figure 1). A mean deviation of 
all curve points  < 10% was targeted, however  < 6% 
was overall easy to achieve. The LOB was 0.05 mg/L, 
based on the experiment with the CRP-depleted serum 
(a small negative mean bit value of −25 was observed). 
The LOD and the LOQ of the functional nephelometric 
CRP assay were 0.5 mg/L and 0.8 mg/L, respectively. 
The assay was found to be linear in the range between 
0.1 mg/L and 300 mg/L. Within-run and between-run 
imprecision data are given in Table 2. The within-run 
coefficients of variation (CVs) ranged from 4.5% to 6.1% 
and between-run CV values were found between 11.3% 
and 18.8%.
Method comparison
We found a good agreement between the CRP values 
(mg/L) obtained by the immunoturbidimetric (X) and the 
functional nephelometric CRP (Y) methods in a concentra-
tion range from 0.1 mg/L to 50 mg/L: Y (CRP by functional 
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Figure 1 Calibration curve of the functional nephelometric CRP assay (BNII).
The start value (bit) represents the light scatter before the reaction takes place. This value is mainly determined by the light scatter proper-
ties of the Intralipid particles used. The next column (marked ‘value bits’) depicts the delta between the final reading and the initial reading. 
For samples containing small amounts of CRP (1:640 and 1:320 dilutions) the effect of CRP agglutination on the light scattering is small (and 
hence the bit value is lower than the initial start value).
Table 2 Imprecision data for the functional nephelometric CRP assay (BNII).
CRP pools assayed by 
nephelometry, mg/L
 
 
Within-run CV (n = 10)  
 
Between-run CV (n = 7)a
Mean, mg/L   SD, mg/L   CV, % Mean, mg/L   SD, mg/L   CV, %
Level 1   2.5   0.1   4.5   –   –   –
Level 2   4.5   0.3   6.1   6.4   1.1   17.6
Level 3   21.6   1.0   4.7   26.1   4.9   18.8
Level 4   65.8   3.0   4.5   68.0   7.7   11.3
aBetween-run imprecision was evaluated on four consecutive days with two analyses each day. However, there was a technical failure in the 
second run of day 4, therefore only seven results were available. (–, not available).
assay; mg/L) = −3.212+1.017X (CRP by immunoturbidi-
metric assay; mg/L); r = 0.884, p < 0.0001. The 95% confi-
dence intervals were [0.87–1.12] for the regression slope 
and [−5.25 to −1.63] for the intercept. Figure 2 shows the 
Passing-Bablok regression curve, while Figure 3 depicts 
the Bland-Altman difference plot between the functional 
and the immunoturbidimetric CRP methods.
In contrast, only a limited agreement was achieved 
between the CRP values obtained by both methods in a 
broad concentration range from 0.1 mg/L to 200 mg/L: Y 
(CRP by functional assay; mg/L) = −10.983+1.635X (CRP by 
immunoturbidimetric assay; mg/L); r = 0.895, p < 0.0001.
Specificity
Figure 4 represents the performance of the affinity chro-
matography method to obtain purified CRP or CRP-
depleted serum. The electropherogram shows a single 
peak in the gamma region, which corresponded with the 
purified CRP. This illustrates that the selectivity of the 
protein binding to phospholine is extremely high.
No significant effect of serum phospholipids (up 
to 345 mg/dL), total cholesterol (up to 7.22 mmol/L), 
HDL-cholesterol (up to 2 mmol/L), triglycerides (up to 
40 mmol/L) and calcium (up to 2.5 mmol/L) was observed 
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on the correlation between the immunological and func-
tional CRP assay.
Discussion
The assay we developed allows measurement of CRP in 
serum or heparin plasma using phosphocholine rich soy oil 
emulsions in the standard clinical range, in addition it can 
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Figure 2 Method comparison functional nephelometric CRP assay 
(BNII) vs. immunoturbidimetric CRP assay (Cobas 8000) in a concen-
tration range from 0.1 mg/L to 50 mg/L.
Passing-Bablok regression line with 95% CI (dashed lines) for 49 
serum samples: Y (CRP by functional assay; mg/L) = −3.212+1.017X 
(CRP by immunoturbidimetric assay; mg/L); r = 0.8837, p < 0.0001. 
Dotted line: Y = X.
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Figure 3 Bland-Altman plot expressing the difference between the 
functional nephelometric CRP assay (BNII) and the immunoturbidi-
metric CRP assay (Cobas 8000) against the mean of both measure-
ments in a concentration range from 0.1 mg/L to 50 mg/L.
The solid line represents the mean difference; the dashed lines 
represent the 95% confidence intervals.
Figure 4 Agarose gel electrophoresis followed by Protur® staining 
(Analis, Namur, Belgium).
Lane 6 shows the diluted human serum pool (total protein concen-
tration 1.5 g/L). Lanes 7–10 represent the purified CRP, showing a 
single peak in the γ region of the electropherogram.
also be used as an assay for hsCRP measurements. When 
compared with the previously described manual functional 
method [18], the nephelometric assay has two advantages. 
At first, we were able to automate the manual method using 
nephelometry with a reaction time of only 12 min. Second, 
we were able to measure CRP as low as 0.5 mg/L; this in con-
trast with the manual method which was not able to detect 
CRP concentrations around the upper reference range (LOD 
7 mg/L). The nephelometric approach offers the advantage 
of being much more sensitive than turbidimetric assays 
[19]. Furthermore, the BNII nephelometer has an inbuilt 
dilution station which allows a broad spectrum of sample 
dilutions to be obtained (from 1:2000 to 1:1) enabling reli-
able results over a very wide concentration range to be gen-
erated without altering the assay program. In addition, the 
default starting sample dilution factor used (1:100), makes 
the method insensitive towards sample matrix effects and 
other interferences. Finally, the variation in serum calcium 
concentration will be negligible compared with the final 
calcium concentration in the cuvette, in view of the large 
excess of calcium ions in the reagent. As the reaction prin-
ciple of the functional nephelometric CRP assay is inde-
pendent of the species, the presented assay is not limited to 
humans, but also offers interesting perspectives for assay-
ing CRP in veterinary medicine [25].
Three groups for cardiovascular risk prediction were 
proposed based on the following cut-off points for hsCRP 
concentrations:  < 1 mg/L for low risk, 1–3 mg/L for mod-
erate risk and  > 3 mg/L for high risk [5]. A lower LOD 
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of  < 1 mg/L and reproducibility data of  < 20% are prerequi-
sites to obtain reliable results and to avoid potential mis-
classification of atherosclerotic risk. Most hsCRP assays 
have a lower LOD of  < 0.3 mg/L [5]. So, in contrast to the 
earlier described manual functional CRP assay [18], the 
present method is suited as a hsCRP assay. In addition, 
common turbidimetry is not sensitive enough to meet the 
required sensitivity for hsCRP measurements.
The assay conditions of the functional nephelometric 
CRP assay correspond with a final phosphocholine con-
centration in the cuvette of about 8 µmol/L, which is about 
four times the Kd value of CRP for phosphocholine [26]. 
In this way, impact of light scattering of the Intralipid® 
particles on the dynamic range of the test was kept to a 
minimum ( ± 1100 bits, which accounts for  ± 10% of the 
total dynamic range of the detection system), while still 
keeping a comfortable phosphocholine binding capac-
ity. In the clinically relevant CRP concentration range 
(0–100 mg/L), the CRP concentrations in the cuvette 
range between 0 and 1 µmol/L. The size distribution of 
the Intralipid lipid particles (diameter: 0.78 ± 0.21 µm) [14] 
makes these particles ideally suited for functional turbi-
dimetric analysis. Due to the multimeric structure of CRP, 
the natural lipid droplets act as scaffolds for the multiva-
lent display of phosphocholine molecules in the newly 
developed functional methods.
The observed imprecison CV results ( < 6.5% for the 
within-run imprecision and  < 19% for the between-run 
imprecision) of the described functional method exceed 
the ones described for the immunoturbidimetric assay 
[27]. However, the functional nephelometric CRP assay 
fulfils the imprecision criteria based on biological vari-
ation (imprecision data of  < 21.1%) [28, 29]. The effect of 
sample turbidity using the functional nephelometric assay 
is very limited because of the high dilution factor of about 
1:180 used in the assay. In addition, the wavelength (840 
nm) chosen for nephelometric readings strongly limits 
optical interference by hemolysis and icterus. A good 
agreement was obtained between the functional nephelo-
metric assay and the immunoturbidimetric assay in a CRP 
concentration range from 0.1 mg/L to 50 mg/L. However, 
a less good correlation was observed for a broader con-
centration range (0.1–200 mg/L), while the functional 
nephelometric assay has shown to be linear in a range of 
0.1–300 mg/L. The small analytical bias ( ± 3 mg/L) and the 
differences in the CRP results generated by the two assays 
can be partly explained by the genetic polymorphism of 
CRP [30] and the effect of phosphocholine-bound CRP 
isoforms. In addition, the functional CRP assay has the 
advantage of not being affected by epitopic variation. 
Furthermore, when using a ‘standard platform’, no instru-
ment’s reading system is capable to span a concentration 
range of four orders of magnitude. As a consequence, it 
is impossible to run clinical samples originating from an 
intensive care unit together with samples for hsCRP deter-
mination using one single assay.
The estimated cost of the described functional neph-
elometric assay would be as low as  ± 0.00001 €/test, 
vs.  ± 0.03 €/test for the manual functional assay [18] 
and  ± 1.0 €/test for an immunological test, this is because 
the assay requires inexpensive reagents, is technically 
simple and does not require the use of antibodies. In addi-
tion, the automated functional method allows a through-
put of 112 tests/h. However, we are aware of the estimated 
cost of such a dedicated instrument as a BNII, but even 
when only functional CRP would be performed, running 
35 samples/day would easily save  ± 800 €/year, which 
is already paying back the entire investment (in a poor 
country with limited resources). Furthermore, macro-
economic benefits (e.g., saving on antibiotics budgets, 
prevention of antibiotic resistance, etc) would be a major 
additional advantage.
This study demonstrates the potential of functional 
nephelometric CRP testing in human medicine. In addi-
tion, it offers interesting perspectives for applications in 
veterinary medicine [25].
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